BridgeBio Pharma, Inc. Common Stock (BBIO) is a publicly traded Healthcare sector company. As of July 5, 2026, BBIO trades at $77.19 with a market cap of $15.12B and a P/E ratio of -20.69. BBIO moved +3.62% today. Year to date, BBIO is +2.27%; over the trailing twelve months it is +80.22%. Its 52-week range spans $21.72 to $84.94. Analyst consensus is strong buy with an average price target of $106.22. Rallies surfaces BBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BBIO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BBIO recently traded at $77.19. Market cap is $15.12B. P/E ratio is -20.69. Revenue is $579.96M.
| Metric | Value |
|---|---|
| Price | $77.19 |
| Market Cap | $15.12B |
| P/E Ratio | -20.69 |
| EPS | $-3.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $84.94 |
| 52-Week Low | $21.72 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $579.96M |
| Net Income | $-729.88M |
| Gross Margin | 95.13% |
19 analysts cover BBIO: 0 strong buy, 18 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $106.22.